electroCore, Inc.
Moat Score — electroCore, Inc.
Total Moat Score
7 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | electroCore holds 170 issued U.S. patents and multiple FDA clearances (migraine, cluster headache, hemicrania continua, paroxysmal hemicrania) for gammaCore — a substantial IP position relative to the company's small size and a genuine technical barrier to direct device replication. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a small-cap device maker with limited manufacturing scale, electroCore has no discernible cost advantage versus larger neuromodulation competitors like CEFALY or established pharmaceutical alternatives. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | With 71.2% of 2025 revenue concentrated in VA Federal Supply Schedule contracts, pricing is largely set through government contracting mechanisms rather than open market leverage, limiting the company's pricing power. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | gammaCore and related devices exhibit no network effect; clinical efficacy and regulatory clearance, not user-base size, drive adoption. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | The long-dated VA Federal Supply Schedule contract (through June 2030) provides revenue stickiness within that channel, but the severe customer concentration this creates is as much a risk as a moat — losing or not renewing this single contract would be highly damaging. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | electroCore's addressable markets (migraine/cluster headache device therapy, fibromyalgia wearables) are not inherently scale-limited in the way a true niche market would be, and the company's small size (~$28 million market cap) reflects limited competitive scale rather than a protected niche. |